Stockscreener 앱 받기
63.62
1.86%
1.06
전일 마감가:
$62.56
열려 있는:
$62.4
하루 거래량:
833.81K
Relative Volume:
0.49
시가총액:
$13.13B
수익:
$2.75B
순이익/손실:
$322.29M
주가수익비율:
82.76
EPS:
0.7687
순현금흐름:
$300.88M
1주 성능:
-2.86%
1개월 성능:
-9.33%
6개월 성능:
-17.61%
1년 성능:
-27.64%
1일 변동 폭
$61.41
$63.76
1주일 범위
$61.15
$66.05
52주 변동 폭
$61.15
$99.56
바이오마린 Stock (BMRN) Company Profile
명칭
Biomarin Pharmaceutical Inc
전화
(415) 506-6700
주소
105 DIGITAL DRIVE, NOVATO, CA
BMRN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| BMRN | 63.64 | 13.13B | 2.75B | 322.29M | 300.88M | 0.7687 |
| VRTX | 448.93 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.47 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 597.75 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.43 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.14 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
바이오마린 Stock (BMRN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-20 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | 개시 | Evercore ISI | Outperform |
| 2023-11-15 | 개시 | Wells Fargo | Overweight |
| 2023-10-23 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | 개시 | Raymond James | Mkt Perform |
| 2023-09-18 | 개시 | UBS | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Perform |
| 2023-07-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-03-21 | 개시 | Bernstein | Underperform |
| 2023-02-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-02-21 | 개시 | Citigroup | Neutral |
| 2023-01-30 | 개시 | BMO Capital Markets | Market Perform |
| 2023-01-18 | 개시 | Canaccord Genuity | Hold |
| 2022-10-31 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-13 | 재개 | Wedbush | Neutral |
| 2022-04-25 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | 재개 | Jefferies | Buy |
| 2021-09-09 | 업그레이드 | Stifel | Hold → Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-04 | 재개 | Guggenheim | Buy |
| 2021-03-01 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-08-20 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-08-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2020-08-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-07-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | 재확인 | Citigroup | Buy |
| 2020-01-28 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-27 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-24 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-23 | 재개 | Citigroup | Buy |
| 2019-04-09 | 재개 | Raymond James | Outperform |
| 2019-01-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-07 | 재확인 | Stifel | Buy |
| 2018-08-03 | 재확인 | Stifel | Buy |
모두보기
바이오마린 주식(BMRN)의 최신 뉴스
Layoff Tracker: J&J, Merck Trimming Workforces in China - BioSpace
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock - Yahoo Finance
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Acquired by Primecap Management Co. CA - MarketBeat
Phenylketonuria Market size is ~700 USD million in 2023, asserts DelveInsight | Pharma Giants: PTC Therapeutics, Homology Medicines, Synlogic, BioMarin Pharmaceuticals - The Globe and Mail
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock - Yahoo Finance
EULAV Asset Management Buys 15,000 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Howe & Rusling Inc. Grows Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical Inc. (BMRN): Among the Best Genomics Stocks to Buy Right Now - Yahoo Finance
Implied Volatility Surging for BioMarin Pharmaceutical (BMRN) Stock Options - MSN
10 Biggest Biotechnology Companies - Investopedia
Sumitomo Mitsui Trust Group Inc. Has $32.06 Million Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin's VOXZOGO Shows Remarkable Height Gains in 452-Child Achondroplasia Study | BMRN Stock News - StockTitan
Comgest Global Investors S.A.S. Trims Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Wolfe Research Initiates Coverage of BioMarin Pharmaceutical (BMRN) with Outperform Recommendation - MSN
Los Angeles Capital Management LLC Acquires New Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin stock touches 52-week low at $65.23 amid challenges - Investing.com India
BioMarin Pharmaceutical (NASDAQ:BMRN) Hits New 1-Year Low on Insider Selling - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Now Covered by Analysts at Wolfe Research - MarketBeat
Biomarin pharmaceutical's CTO sells $350k in stock By Investing.com - Investing.com Nigeria
Biomarin pharmaceutical's CTO sells $350k in stock - Investing.com India
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Not Flying Under The Radar - Simply Wall St
WCM Investment Management LLC Has $1.20 Million Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
abrdn Life Sciences Investors declares $0.50 dividend - MSN
Principal Financial Group Inc. Sells 191,421 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
How To Trade (BMRN) - Stock Traders Daily
National Pension Service Grows Stock Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Here’s Why BioMarin Aristotle Large Cap Growth Strategy Divested From Pharmaceutical (BMRN) - Insider Monkey
Robeco Institutional Asset Management B.V. Buys 128,807 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin to Participate in Three Upcoming Investor Conferences - StockTitan
BioMarin Pharmaceutical (NASDAQ:BMRN) Upgraded at Wedbush - MarketBeat
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term - MSN
BioMarin Pharmaceutical Inc.: Enhancement of Enzyme Replacement Therapy (ERT) Portfolio - Smartkarma
CAMP4 Analyst Highlights Rare Disease Platform Potential - Benzinga
BioMarin's SWOT analysis: rare disease biotech stock faces growth challenges - Investing.com
AlphaCentric Advisors LLC Purchases 16,000 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In - MSN
Is BioMarin (BMRN) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance
BioMarin (BMRN) Upgraded to Buy: Here's Why - Yahoo Finance UK
BMRN vs. INCY: Which Stock Is the Better Value Option? - Yahoo Finance
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term - Yahoo Finance
FY2024 Earnings Forecast for BMRN Issued By Leerink Partnrs - MarketBeat
F M Investments LLC Buys New Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Rice Hall James & Associates LLC - MarketBeat
9 Best Biotech Stocks Of November 2024 - Forbes
Beyond the Balance Sheet: What SWOT Reveals About Biomarin Pharmaceutical Inc (BMRN) - Yahoo Finance UK
Beyond the Balance Sheet: What SWOT Reveals About Biomarin Pharm - GuruFocus.com
Cantor Fitzgerald Issues Positive Estimate for BMRN Earnings - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q3 2024 Earnings Call Transcript - Insider Monkey
BioMarin Pharmaceutical Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
(BMRN) Proactive Strategies - Stock Traders Daily
Short Interest in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Expands By 5.9% - MarketBeat
바이오마린 (BMRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):